Linked Life Data

11727304

Source:http://linkedlifedata.com/resource/pubmed/id/11727304

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-11-30
pubmed:abstractText
Alzheimer's disease is the most common form of dementia and a major public health problem. The amyloid hypothesis suggests that Alzheimer's disease is due to the abnormal accumulation of amyloid-beta protein (A beta) in affected brain regions. Rational therapies aimed at reducing amyloid burden in brain are currently being pursued in preclinical and early clinical development. This review summarizes recent progress in understanding the beta- and gamma-secretase activities required for the formation of A beta peptide and discusses therapeutic strategies aimed at inhibiting these activities. Recent progress in the identification of small molecule inhibitors of these secretases is also reviewed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1367-6733
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
390-401
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Progress towards testing the amyloid hypothesis: inhibitors of APP processing.
pubmed:affiliation
DuPont Pharmaceuticals Company, Chemical and Physical Sciences, Experimental Station, E500/2805, Route 141 & Henry Clay Road, Wilmington, DE 19880-0500, USA. Richard.E.Olson@DuPontpharma.com
pubmed:publicationType
Journal Article, Review